(19)
(11) EP 1 661 911 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.02.2013 Bulletin 2013/07

(45) Mention of the grant of the patent:
07.11.2012 Bulletin 2012/45

(21) Application number: 04772501.5

(22) Date of filing: 31.08.2004
(51) International Patent Classification (IPC): 
C07K 14/31(2006.01)
A61P 37/08(2006.01)
A61K 39/085(2006.01)
C12N 15/31(2006.01)
(86) International application number:
PCT/JP2004/012545
(87) International publication number:
WO 2005/023853 (17.03.2005 Gazette 2005/11)

(54)

PROTEASE-RESISTANT MODIFIED SEB AND VACCINE CONTAINING THE SAME

PROTEASE-RESISTENTE SEB-VARIANTE UND DIESE ENTHALTENDER IMPFSTOFF

VARIANTE DE L'ENTEROTOXINE B DU STAPHYLOCOQUE DORE RESISTANT AUX PROTEASES ET VACCIN EN CONTENANT


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 05.09.2003 JP 2003314187

(43) Date of publication of application:
31.05.2006 Bulletin 2006/22

(73) Proprietor: The Chemo-Sero-Therapeutic Research Institute
Kumamoto-shi Kumamoto 860-8568 (JP)

(72) Inventors:
  • NAKASHIMA, Toshihiro c/o JURIDICAL FOUNDATION THE
    Kikuchi-shi Kumamoto-ken 869-1298 (JP)
  • SASAKI, Takumi c/o JURIDICAL FOUNDATION THE
    Kikuchi-shi Kumamoto-ken 869-1298 (JP)
  • NISHIHARA, Tsukasa c/o JURIDICAL FOUNDATION THE
    Kikuchi-shi Kumamoto-ken 869-1298 (JP)
  • TAKEMOTO, Sumiyo c/o JURIDICAL FOUNDATION THE
    Kumamoto-shi, Kumamoto-ken 860-8568 (JP)
  • SAKATA, Atsuko
    Kumamoto-ken 861-5515 (JP)
  • OHKUCHI, Masao
    Saitama-ken 359-0041 (JP)
  • KOSHI, Tomoyuki
    Saitama-ken 353-0006 (JP)
  • EDANO, Toshiyuki
    Saitama-ken 350-0034 (JP)

(74) Representative: Vossius & Partner 
Siebertstrasse 4
81675 München
81675 München (DE)


(56) References cited: : 
EP-A- 1 055 429
WO-A1-99/40935
WO-A-93/14634
JP-A- 8 500 328
   
  • PAPAGEORGIOU A C ET AL: "Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site" STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US, vol. 3, no. 8, 1 August 1995 (1995-08-01), pages 769-779, XP004587900 ISSN: 0969-2126
  • WOODY MA. ET AL: 'STAPHYLOCOCCAL ENTEROTOXIN B MUTANTS (N23K AND F44S):BIOLOGICAL EFFECTS AND VACCINE POTENTIAL IN A MOUSE MODEL' VACCINE vol. 15, no. 2, 1997, pages 133 - 139, XP004054362
  • BOLES JW.ET AL.: 'GENERATION OF PROTECTIVE IMMUNITY BY INACTIVATED RECOMBINANT STAPHYLOCOCCAL ENTEROTOXIN B VACCINE IN NINHUMAN PRIMATES AND IDENTIFICATION OF CORRELATES OF IMMUNITY' CLIN.IMMUNOL. vol. 108, no. 1, July 2003, pages 51 - 59, XP002903427
  • MAGAGNOLI C, ET AL.: 'MUTATIONS IN THE A SUBUNIT AFFECT YIELD, STABILITY, AND PROTEASE OF NONTOXIC DERIVATIVES OF HEAT-LABILE ENTEROTOXIN' INFECT.IMMUN, vol. 64, no. 12, 1996, pages 5434 - 5438, XP002970709
  • SPERO L. ET AL: 'EFFECT OF SINGLE PEPTIDE BOND SCISSION BY TRYPSIN ON THE STRUCTURE AND ACTIVITY OF STAPHYLOCCAL ENTEROTOXIN B,' J.BIOL.CHEM. vol. 248, no. 21, 1973, pages 7289 - 7294, XP002903428
  • ROGGIANI M. ET AL: 'ANALYSIS OF TOXICITY OF STREPTOCOCCAL PYROGENIC EXOTOXIN A MUTANTS' INFECT.IMMUN. vol. 65, no. 7, 1997, pages 2868 - 2875, XP002067015
  • KLINE JB ET AL: 'ANALYSIS OF THE SUPERANTIGENIC ACTIVITY OF MUTANT AND ALLELIC FORMS OF STREPTOCOCCAL PYROGENIC EXOTOXIN A.' INFECT IMMUN. vol. 65, no. 3, 1996, pages 861 - 869, XP002066999
  • DERESIEWICZ RL ET AL: 'MUTATIONS AFFECTING THE ACTIVITY OF TOXIC SHOCK SYNDROME TOXIN-1' BIOCHEMISTRY vol. 33, no. 43, 1994, pages 12844 - 12851, XP002903429
  • LEDER L.ET AL: 'A MUTATIONAL ANALYSIS OF THE BINDING OF STAPHYLOCOCCAL ENTEROTOXINS B AND C3 TO THE T CELL RECEPTOR BETA CHAIN ANDMAJOR HISTOCOMPATIBILITY COMPLEX CLASS II' J.EXP.MED. vol. 187, no. 6, 1998, pages 823 - 833, XP002903430
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).